- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05970809
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss (CS-SAGA-001)
A Randomised, Evaluator-Blinded, Two-Arm Study To Evaluate The Safety And Efficacy of a Novel Microneedle and Laser-Based Medical Device For The Treatment of Androgenetic Alopecia in Adult Males
The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss.
Two different device configurations are being explored as part of this study. Device A has novel microneedles, lasers, and additional metal microneedles, while Device B only has novel microneedles and lasers.
Participants will receive 12 treatments with either Device A or Device B over the course of 24 weeks. Treatments will be performed on-site every two weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will have the medical tests or procedures described below:
- Subjects will be asked about their previous medical history and current medications.
- Brief physical examinations will be performed, including a visual inspection of the scalp.
- Questions about medical history (including previous and current medication use) will be asked.
- Two types of photos will be taken: 1) "global photos", which are general photos of the subject's scalp, and 2) "macro photos", which are close-up photos of a part of the subject's scalp.
- Questions about treatment-related issues or unpleasantness will be asked.
- Subjects will be asked to rate the improvement they see in their photos.
- Subjects will be asked to rate their satisfaction with the treatment.
Participants will also be asked to record changes in medications, changes in medical treatments, and major life changes (such as major dietary changes, exercise changes, changes in life stressors, etc.) in a diary for the duration of treatment. They should also make note of any suspected side effects or issues they believe are related to the treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ana I Villalba
- Phone Number: +34 647160346
- Email: ana@stimusil.com
Study Contact Backup
- Name: Siddhi BC Lama, PhD
- Email: siddhi@stimusil.com
Study Locations
-
-
-
Ankara, Turkey
- Recruiting
- Ankara Bilkent Şehir Hastanesi Dermatoloji Klini
-
Contact:
- Akın Aktaş, MD
- Email: aaktas@ybu.edu.tr
-
Istanbul, Turkey
- Recruiting
- İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü Deri ve Zührevi Hastalıklar Ana Bilim Dalı Kocamustafa Paşa
-
Contact:
- Server Serdaroğlu, MD
- Email: server.serdaroglu@iuc.edu.tr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is willing to sign an informed consent form
- Subject is within the age group of 22-55 years (including both ages)
- Subject is male
- Subject has AGA with a Stage IIa-V Hamilton-Norwood classification
- Subject's skin is within Fitzpatrick Skin Types I-IV
Exclusion Criteria:
Subjects who have used any formulation or application/administration or type of treatment for disorders of the skin or scalp within 180 days prior to screening, including but not limited to the following treatments:
- Anti-inflammatory medications, including topical steroids
- Antifungal
- Skin, nail, hair rejuvenation supplementation, or IV infusions (includes vitamin, minerals, herbals, etc.)
- Hair growth shampoos, conditioners, and topicals
- Topical, dermal or oral minoxidil, finasteride, or dutasteride
- Hair growth stimulation treatments, i.e. PRP, stem cells, exosomes, growth factors, microneedling, mesotherapy
- LED or low level laser therapy treatments, ie. laser helmets, laser caps, and laser combs
- Infrared saunas
- Subjects with alopecia other than AGA, such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia
- Subjects with a history of bleeding disorders
- Subjects on anticoagulant medications (aspirin, warfarin, heparin)
- Subject on autoimmune suppressant medications or suffering autoimmune diseases (e.g. humira)
- Subjects with an active infection at the local site
- Subjects with keloidal tendencies
- Subjects with chronic dermatological conditions affecting the scalp (e.g. eczema, psoriasis, etc.)
- Subjects with hepatic or renal disease, epilepsy, or any other major medical illness*
- Subjects that have undergone evaluation to rule out other causes of hair loss, because underlying causes (e.g., iron deficiency, lupus, thyroid disease, telogen effluvium, post-pregnancy, polycystic ovary, chemotherapy, etc.) would preclude assessment of performance in an androgenetic alopecia trial
- Subjects who are photosensitive or are using photosensitive drugs or topicals.
- Subjects who are taking anxiolytics medications
- Subjects who have been on hormone inhibitors or on hormone replacement therapy in the last 180 days
- Subjects who are at high risk of seizures
- Subjects who have a malignancy or a history of malignancies affecting the scalp
- Subjects that have undergone hair transplantation, scalp reduction, radiation to the scalp or chemotherapy within their lifetime.
- Subjects with current hair weaves, hair extensions, scalp tattoos, or who use occlusive wigs.
- Subjects who have used semi-permanent hair products (e.g. color, texturizers or relaxers) within 30 days prior to screening.
- Subjects with hair shorter than one-half inch (approximately 1.2 cm).
- Subjects who are unable to make regular follow-up visits.
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative sites, or individuals who are directly affiliated with the study at the investigative sites, or individuals directly affiliated with the study sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device A
Device configuration A has metal and novel microneedles and lasers.
|
Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
|
Experimental: Device B
Device configuration B has novel microneedles and lasers.
|
Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in terminal hair density
Time Frame: 24 weeks
|
Changes in terminal hair density at the 24-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi ≥ 60%, where pi is the true percentage of responders in the study population.
|
24 weeks
|
Change in terminal hair density
Time Frame: 16 weeks
|
Changes in terminal hair density at the 16-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi ≥ 60%, where pi is the true percentage of responders in the study population.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hair thickness
Time Frame: 16 weeks
|
Increases and/or decreases in hair diameter at the 16-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change.
|
16 weeks
|
Change in hair thickness
Time Frame: 24 weeks
|
Increases and/or decreases in hair diameter at the 24-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Server Serdaroğlu, MD, İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS-SAGA-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Indonesia UniversityRecruiting
-
Cassiopea SpAICON Clinical Research; Canfield Scientific Inc.; Ergomed PLC; Pharmapace IncRecruitingAlopecia, AndrogeneticGermany, United States, Poland
-
University of ArizonaTransdermal Cap, Inc.Not yet recruitingAndrogenetic Alopecia
-
Gregory L Smith, MD, MPHRecruitingAndrogenetic AlopeciaUnited States
-
Indonesia UniversityCompletedAndrogenetic AlopeciaIndonesia
Clinical Trials on SAGA-001 (A)
-
University of ChicagoNorthwestern University; Chicago Public Schools; Crown Family Philanthropies; Paul... and other collaboratorsUnknownEducational Achievement
-
Karolinska InstitutetCompleted
-
University of ChicagoNorthwestern University; Chicago Public Schools; Abdul Latif Jameel Poverty Action... and other collaboratorsUnknown
-
National Institute of Allergy and Infectious Diseases...SuspendedRespiratory Syncytial Virus InfectionsUnited States
-
GluBio Therapeutics Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesUnited States
-
Hangzhou GluBio Pharmaceutical Co., Ltd.Not yet recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid MalignancyChina
-
Yungjin Pharm. Co., Ltd.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Anthera PharmaceuticalsCompletedSickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive CrisisUnited States
-
Beat AML, LLCRecruitingPreviously Untreated Acute Myeloid LeukemiaUnited States
-
Toll Biotech Co. Ltd. (Beijing)Recruiting